Is There Re-staging Surgery Necessity for Borderline Ovarian Tumors

Abstract

Objective

This study assessed the necessity of surgical re-staging in women with borderline ovarian tumors (BOTs) and evaluated the impact of complete surgical staging, lymphadenectomy, and omentectomy on disease recurrence and survival.

Methods

We retrospectively reviewed the medical records of patients with BOTs. A total of 901 patients were eligible for inclusion in the study, and we evaluated some of the variables and clinical/surgical characteristics of the cases. The effects of the type of surgical procedure, surgical staging, and complete or incomplete staging on recurrence were calculated. The rates of disease-free survival, overall survival, and recurrence were compared according to complete surgical staging. A Cox regression analysis was performed to identify potential prognostic factors, and survival curves were constructed using the Kaplan-Meier method.

Results

The overall recurrence rate was 13.9%, and recurrence was comparable between the complete surgical staging group and the incomplete groups (P>0.05). The performance of complete surgical staging did not show an effect on long-term survival, and complete surgical staging, omentectomy, and lymphadenectomy had no effect on recurrence. In multivariate analyses, only radical surgery and adjuvant chemotherapy were risk factors for the recurrence of BOTs. Furthermore, we found that omentectomy led to a relatively low recurrence rate in patients with International Federation of Gynecology and Obstetrics (FIGO) stage > I (P=0.022).

Conclusion

Our results suggest that complete surgical staging should be considered a standard treatment for patients with advanced stage BOTs but not for those at FIGO stage I. It might be safe to reduce the scope of surgical procedures in patients with early-stage BOTs. However, it is not necessary to perform re-staging operations for BOTs with a macroscopically normal extra-ovarian appearance.

Keywords

borderline ovarian tumor / staging surgery / management / recurrence

References

[1] ColomboN, SessaC, du BoisA, et al.. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol, 2019, 30(5): 672-705

[2] BourdelN, HuchonC, Abdel WahabC, et al.. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF). Eur J Obstet Gynecol Reprod Biol, 2021, 256: 492-501

[3] PlettH, HarterP, AtasevenB, et al.. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecol Oncol, 2020, 157(2): 411-417

[4] MoriceP, UzanC, FauvetR, et al.. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol, 2012, 13(3): e103-e115

[5] De DeckerK, JarochKH, BartJ, et al.. Borderline ovarian tumor frozen section diagnoses with features suspicious of invasive cancer: a retrospective study. J Ovarian Res, 2021, 14(1): 139

[6] YoshidaH, TanakaH, TsukadaT, et al.. Diagnostic Discordance in Intraoperative Frozen Section Diagnosis of Ovarian Tumors: A Literature Review and Analysis of 871 Cases Treated at a Japanese Cancer Center. Int J Surg Pathol, 2021, 29(1): 30-38

[7] LabanM, ChenX, GuoB. Seromucinous and Mucinous Borderline Ovarian Tumors: We Need to Know More. Reprod Sci, 2022, 30(5): 1684-1685

[8] MatsuoK, MachidaH, MandelbaumRS, et al.. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecol Oncol, 2019, 153(2): 230-237

[9] ChevrotA, PougetN, BatsAS, et al.. Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group. Gynecol Oncol, 2020, 157(1): 29-35

[10] ChevrotA, HéquetD, FauconnierA, et al.. Impact of surgical restaging on recurrence in patients with borderline ovarian tumors: A meta-analysis. Eur J Obstet Gynecol Reprod Biol, 2020, 248: 227-232

[11] MayJ, SkorupskaiteK, CongiuM, et al.. Borderline Ovarian Tumors: Fifteen Years’ Experience at a Scottish Tertiary Cancer Center. Int J Gynecol Cancer, 2018, 28(9): 1683-1691

[12] JungHJ, ParkJY, KimDY, et al.. Low value of staging in detecting extraovarian occult metastasis in mucinous borderline ovarian tumors. Int J Gynecol Cancer, 2020, 30(11): 1780-1783

[13] ChevrotA, HéquetD, FauconnierA, et al.. Impact of surgical restaging on recurrence in patients with borderline ovarian tumors: A meta-analysis. Eur J Obstet Gynecol Reprod Biol., 2020, 248: 227-232

[14] AbdallahR, ChamsyD, DagherC, et al.. Borderline ovarian tumors: a retrospective cohort study on single institution experience, practice patterns and outcomes. J Obstet Gynaecol, 2022, 42(8): 3600-3604

[15] ShimSH, KimSN, JungPS, et al.. Impact of surgical staging on prognosis in patients with borderline ovarian tumours: A meta-analysis. Eur J Cancer, 2016, 54: 84-95

[16] BendifallahS, NikpayamM, BallesterM, et al.. New Pointers for Surgical Staging of Borderline Ovarian Tumors. Ann Surg Oncol, 2016, 23(2): 443-449

[17] GuvenalT, DursunP, HasdemirPS, et al.. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study. Gynecol Oncol, 2013, 131(3): 546-550

[18] GokcuM, GungordukK, AşıcıoğluO, et al.. Borderline ovarian tumors: clinical characteristics, management, and outcomes - a multicenter study. J Ovarian Res, 2016, 9(1): 66

[19] TrillschF, MahnerS, VettorazziE, et al.. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer, 2015, 112(4): 660-666

[20] RomeoM, PonsF, BarretinaP, et al.. Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor. World J Surg Oncol, 2013, 11: 13

[21] LeeJY, KimHS, ChungHH, et al.. The role of omentectomy and random peritoneal biopsies as part of comprehensive surgical staging in apparent early-stage epithelial ovarian cancer. Ann Surg Oncol, 2014, 21(8): 2762-2766

[22] De DeckerK, SpethS, Ter BruggeHG, et al.. Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease. Gynecol Oncol, 2017, 144(2): 285-289

[23] MatsuoK, MachidaH, GrubbsBH, et al.. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecol Oncol, 2020, 157(1): 21-28

[24] QianXQ, HuaXP, WuJH, et al.. Clinical Predictors of Recurrence and Prognostic Value of Lymph Node Involvement in the Serous Borderline Ovarian Tumor. Int J Gynecol Cancer, 2018, 28(2): 279-284

[25] FanY, ZhangYF, WangMY, et al.. Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis. Gynecol Oncol, 2021, 162(3): 797-803

[26] NusbaumDJ, MandelbaumRS, MachidaH, et al.. Significance of lymph node ratio on survival of women with borderline ovarian tumors. Arch Gynecol Obstet, 2020, 301(5): 1289-1298

[27] KristensenGS, SchledermanaD, MogensenO, et al.. The value of random biopsies, omentectomy, and hysterectomy in operations for borderline ovarian tumors. Int J Gynecol, 2014, 24(5): 874-879